Menactra

SKU: MENACTRA-SP Category: Tag:

Description

Menactra vaccine is Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate indicated for active immunization to prevent invasive Meningococcal disease caused by N meningitidis serogroups A, C, Y and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Immunization guideline:

Primary Vaccination:

  • Children 9 through 23 months of age: Two doses, three months apart
  • Individuals 2 through 55 years of age: A single dose

Booster Vaccination:

  • A single booster dose may be given to individuals 15 through 55 years of age at continued risk for meningococcal disease, if at least 4 years have elapsed since the prior dose

For latest IAP updates see revised immunization schedule.

Additional information

manufacturer

Sanofi Pasteur

country-of-manufacture

USA

vaccine-type

MeningococcalACYW-135 (conjugate vaccine)

pharmaceutical-form

Liquid

package-size

1 Dose

route-of-administration

Intramuscular

preservative

None

Contraindications

Severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide, diphtheria toxoid or CRM-containing vaccine, or to any component of Menactra vaccine